Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

Last updated: June 30, 2025
Sponsor: Sanofi
Overall Status: Completed

Phase

3

Condition

Multiple Sclerosis

Neurologic Disorders

Memory Loss

Treatment

Teriflunomide

Teriflunomide HMR1726

Placebo to match Teriflunomide

Clinical Study ID

NCT04410978
EFC16033
U1111-1238-1418
2020-000637-41
  • Ages 18-55
  • All Genders

Study Summary

Primary Objective:

To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS

Secondary Objective:

To assess efficacy of SAR442168 compared to teriflunomide (Aubagio) on disability progression, MRI lesions, cognitive performance and quality of life To evaluate the safety and tolerability of daily SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168

Eligibility Criteria

Inclusion

Inclusion criteria :

  • The participant must be 18 to 55 years of age, inclusive, at the time of signing theinformed consent

  • The participant must have been diagnosed with RMS according to the 2017 revision ofthe McDonald diagnostic criteria

  • The participant has an expanded disability status scale (EDSS) score ≤5.5 at thefirst Screening Visit

  • The participant must have at least 1 of the following prior to screening:

  • ≥1 documented relapse within the previous year OR

  • ≥2 documented relapses within the previous 2 years, OR

  • ≥1 documented Gd enhancing lesion on an MRI scan within the previous year

  • Contraceptive use by men or women should be consistent with local regulationsregarding the methods of contraception for those participating in clinical studies

  • Male participants are eligible to participate if they agree to the following duringthe intervention period and until accelerated elimination procedure:

  • Refrain from donating sperm

Plus either:

  • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR

  • Must agree to use contraception/barrier as detailed below:

Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant

  • A female participant is eligible to participate if she is not pregnant orbreastfeeding, and at least one of the following conditions apply:

  • Is not a WOCBP OR

  • Is a WOCBP and agrees to use a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency,during the intervention period and until accelerated elimination procedure iscompleted (or for at least 10 days after the last dose of SAR442168, if thecase was unblinded)

  • A WOCBP must have a negative highly sensitive pregnancy test at screening and within 24hours before the first dose of study intervention.

  • If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serumpregnancy test is required. In such cases, the participant must be excluded fromparticipation if the serum pregnancy result is positive.

  • The Investigator is responsible for review of medical history, menstrual history,and recent sexual activity to decrease the risk for inclusion of a woman with anearly undetected pregnancy.

  • The participant must have given written informed consent prior to undertaking anystudy related procedure. This includes consent to comply with the requirements andrestrictions listed in the informed consent form (ICF) and in this protocol. Incountries where the legal age of maturity is greater than 18 years, a specific ICFfor such legally minor participants must also be signed by the participant's legallyauthorized representative

Exclusion

Exclusion criteria:

  • The participant has been diagnosed with primary progressive multiple sclerosis (PPMS) according to the 2017 revision of the McDonald diagnostic criteria or withnonrelapsing secondary progressive multiple sclerosis (SPMS)

  • The participant has a history of infection or may be at risk for infection includingbut not limited to: HIV, transplantation, live attenuated vaccines, progressivemultifocal leukoencephalopathy, tuberculosis, any persistent chronic or activerecurring infection

  • Clinically significant laboratory abnormalities (including evidence of liver injury)or electrocardiogram abnormalities at Screening.

  • The participant has conditions or situations that would adversely affectparticipation in this study, including but not limited to:

  • A short life expectancy due to pre-existing health condition(s) as determinedby their treating neurologist

  • Medical condition(s) or concomitant disease(s) making them nonevaluable for theprimary efficacy endpoint or that would adversely affect participation in thisstudy, as judged by the Investigator

  • A requirement for concomitant treatment that could bias the primary evaluation

  • The participant has a history of or currently has concomitant medical or clinicalconditions that would adversely affect participation in this study

  • At screening, the participant is positive for hepatitis B surface antigen and/orhepatitis B core antibody and/or is positive for hepatitis C antibody

  • The participant has any of the following:

  • A bleeding disorder or known platelet dysfunction at any time prior to thescreening visit

  • A platelet count <150 000/μL at the screening visit

  • The participant has a lymphocyte count below the lower limit of normal (LLN) at thescreening visit

  • The presence of psychiatric disturbance or substance abuse

  • Prior/concomitant therapy

  • The participant is receiving potent and moderate inducers of cytochrome P450 (CYP) 3A or potent inhibitors of CYP2C8 hepatic enzymes

  • The participant is receiving anticoagulant/antiplatelet therapies

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Total Participants: 974
Treatment Group(s): 5
Primary Treatment: Teriflunomide
Phase: 3
Study Start date:
June 30, 2020
Estimated Completion Date:
July 15, 2024

Study Description

This was an event-driven (6-month confirmed disability worsening [CDW]) trial with a variable treatment duration (end-of-study [EOS] duration: up to approximately 48 months).

Connect with a study center

  • Investigational Site Number :0400004

    Linz, 4021
    Austria

    Site Not Available

  • Investigational Site Number :1120004

    Vitebsk, 210037
    Belarus

    Site Not Available

  • Investigational Site Number :1120005

    Vitebsk, 210009
    Belarus

    Site Not Available

  • Investigational Site Number :1000002

    Pleven, 5800
    Bulgaria

    Site Not Available

  • Investigational Site Number :1000005

    Plovdiv, 4000
    Bulgaria

    Site Not Available

  • Investigational Site Number :1000001

    Sofia, 1431
    Bulgaria

    Site Not Available

  • Investigational Site Number :1000004

    Sofia, 1113
    Bulgaria

    Site Not Available

  • Investigational Site Number :1000006

    Sofia, 1431
    Bulgaria

    Site Not Available

  • Investigational Site Number :1000008

    Sofia, 1407
    Bulgaria

    Site Not Available

  • Investigational Site Number :1000009

    Sofia, 1680
    Bulgaria

    Site Not Available

  • Investigational Site Number :1240016

    Vancouver, British Columbia V6T 2B5
    Canada

    Site Not Available

  • Investigational Site Number :1240003

    Ottawa, Ontario K1H 8L6
    Canada

    Site Not Available

  • Investigational Site Number :1240013

    Toronto, Ontario M5B 1W8
    Canada

    Site Not Available

  • Investigational Site Number :1240006

    Gatineau, Quebec J8Y 1W2
    Canada

    Site Not Available

  • Investigational Site Number 1240019

    West Vancouver, V7T 1C5
    Canada

    Site Not Available

  • Investigational Site Number :1560022

    Baotou, 014010
    China

    Site Not Available

  • Investigational Site Number :1560001

    Beijing, 100730
    China

    Site Not Available

  • Investigational Site Number :1560006

    Beijing, 100034
    China

    Site Not Available

  • Investigational Site Number :1560009

    Beijing, 100730
    China

    Site Not Available

  • Investigational Site Number :1560010

    Beijing, 100050
    China

    Site Not Available

  • Investigational Site Number :1560012

    Beijing, 100053
    China

    Site Not Available

  • Investigational Site Number :1560021

    Beijing, 100853
    China

    Site Not Available

  • Investigational Site Number :1560023

    Beijing, 100191
    China

    Site Not Available

  • Investigational Site Number :1560025

    Beijing, 100730
    China

    Site Not Available

  • Investigational Site Number :1560004

    Changchun, 130021
    China

    Site Not Available

  • Investigational Site Number :1560015

    Changsha, 410008
    China

    Site Not Available

  • Investigational Site Number :1560005

    Chengdu, 610041
    China

    Site Not Available

  • Investigational Site Number :1560019

    Chongqing, 400016
    China

    Site Not Available

  • Investigational Site Number :1560035

    Fuzhou, 350005
    China

    Site Not Available

  • Investigational Site Number :1560002

    Guangzhou, 510630
    China

    Site Not Available

  • Investigational Site Number :1560016

    Guangzhou, 510080
    China

    Site Not Available

  • Investigational Site Number :1560028

    Guangzhou, 510515
    China

    Site Not Available

  • Investigational Site Number :1560027

    Hohhot, 010050
    China

    Site Not Available

  • Investigational Site Number :1560042

    Nanjing, 210029
    China

    Site Not Available

  • Investigational Site Number :1560044

    Nanjing, 210008
    China

    Site Not Available

  • Investigational Site Number :1560003

    Shanghai, 200040
    China

    Site Not Available

  • Investigational Site Number :1560018

    Shenyang, 110004
    China

    Site Not Available

  • Investigational Site Number :1560014

    Shijiazhuang, 050000
    China

    Site Not Available

  • Investigational Site Number :1560008

    Taiyuan, 030001
    China

    Site Not Available

  • Investigational Site Number :1560020

    Tianjin, 300052
    China

    Site Not Available

  • Investigational Site Number :1560011

    Wuhan, 430030
    China

    Site Not Available

  • Investigational Site Number :1560017

    Xi'an, 710038
    China

    Site Not Available

  • Investigational Site Number :1560033

    Yinchuan, 750004
    China

    Site Not Available

  • Investigational Site Number :2030004

    Hradec Kralove, 50005
    Czechia

    Site Not Available

  • Investigational Site Number :2030009

    Pardubice, 53203
    Czechia

    Site Not Available

  • Investigational Site Number :2030003

    Teplice, 415 29
    Czechia

    Site Not Available

  • Investigational Site Number :2030007

    Zlin, 76275
    Czechia

    Site Not Available

  • Investigational Site Number :2080003

    Aalborg, 9100
    Denmark

    Site Not Available

  • Investigational Site Number :2080001

    Esbjerg, 6700
    Denmark

    Site Not Available

  • Investigational Site Number :2080005

    Holstebro, 7500
    Denmark

    Site Not Available

  • Investigational Site Number 2330003

    Pärnu, 80010
    Estonia

    Site Not Available

  • Investigational Site Number :2330001

    Tallinn, 11315
    Estonia

    Site Not Available

  • Investigational Site Number :2330002

    Tartu, 50406
    Estonia

    Site Not Available

  • Investigational Site Number :2460003

    Helsinki, 00180
    Finland

    Site Not Available

  • Investigational Site Number :2460001

    Tampere, 33520
    Finland

    Site Not Available

  • Investigational Site Number :2460002

    Turku, 20520
    Finland

    Site Not Available

  • Investigational Site Number :2760001

    Dresden, 01307
    Germany

    Site Not Available

  • Investigational Site Number :2760019

    Düsseldorf, 40225
    Germany

    Site Not Available

  • Investigational Site Number :2760016

    Hamburg, 22179
    Germany

    Site Not Available

  • Investigational Site Number :2760008

    Münster, 48149
    Germany

    Site Not Available

  • Investigational Site Number :2760004

    Rostock, 18055
    Germany

    Site Not Available

  • Investigational Site Number :2760011

    Ulm, 89081
    Germany

    Site Not Available

  • Investigational Site Number : 3440001

    Shatin, NT,
    Hong Kong

    Site Not Available

  • Investigational Site Number :3800002

    Pozzilli, Isernia 86077
    Italy

    Site Not Available

  • Investigational Site Number :3800007

    Orbassano, Torino 10043
    Italy

    Site Not Available

  • Investigational Site Number :3800011

    Bergamo, 24127
    Italy

    Site Not Available

  • Investigational Site Number :3800015

    Catania, 95123
    Italy

    Site Not Available

  • Investigational Site Number :3800012

    Firenze, 50134
    Italy

    Site Not Available

  • Investigational Site Number :3800014

    Genova, 16132
    Italy

    Site Not Available

  • Investigational Site Number :3800001

    Milano, 20132
    Italy

    Site Not Available

  • Investigational Site Number :3800010

    Milano, 20133
    Italy

    Site Not Available

  • Investigational Site Number :3800003

    Napoli, 80131
    Italy

    Site Not Available

  • Investigational Site Number :3800006

    Napoli, 80131
    Italy

    Site Not Available

  • Investigational Site Number :3800008

    Pavia, 27100
    Italy

    Site Not Available

  • Investigational Site Number :3800005

    Roma, 00152
    Italy

    Site Not Available

  • Investigational Site Number :3800009

    Roma, 00168
    Italy

    Site Not Available

  • Investigational Site Number :3800013

    Roma, 00189
    Italy

    Site Not Available

  • Investigational Site Number :3920016

    Chiba-shi, Chiba 260-8677
    Japan

    Site Not Available

  • Investigational Site Number :3920008

    Koriyama-shi, Fukushima 963-8052
    Japan

    Site Not Available

  • Southern Tohoku medical clinic 7-161, Yatsuyamada, Koriyama-shi, Fukushima_Investigational Site Number :3920008

    Koriyama-shi, Fukushima 963-8052
    Japan

    Site Not Available

  • Investigational Site Number :3920012

    Tsukuba-shi, Ibaraki 305-0005
    Japan

    Site Not Available

  • Investigational Site Number :3920022

    Morioka-shi, Iwate 020-8505
    Japan

    Site Not Available

  • Investigational Site Number :3920005

    Niigata-shi, Niigata 951-8520
    Japan

    Site Not Available

  • Investigational Site Number :3920004

    Moriguchi-shi, Osaka 570-8507
    Japan

    Site Not Available

  • Investigational Site Number :3920001

    Osaka-shi, Osaka 556-0016
    Japan

    Site Not Available

  • Investigational Site Number :3920018

    Kawagoe-shi, Saitama 350-8550
    Japan

    Site Not Available

  • Investigational Site Number :3920014

    Bunkyo-ku, Tokyo 113-8431
    Japan

    Site Not Available

  • Investigational Site Number :3920003

    Kodaira-shi, Tokyo 187-8551
    Japan

    Site Not Available

  • Investigational Site Number :3920010

    Ota-ku, Tokyo 146-0065
    Japan

    Site Not Available

  • Investigational Site Number :3920013

    Shinjuku-ku, Tokyo 162-8666
    Japan

    Site Not Available

  • Investigational Site Number :3920009

    Ube-shi, Yamaguchi 755-8505
    Japan

    Site Not Available

  • Investigational Site Number :3920023

    Sagamihara-shi, 252-0392
    Japan

    Site Not Available

  • NHO Sagamihara National Hospital Minami-ku Sakuradai 18-1, Sagamihara-shi, Kanagawa-ken_Investigational Site Number :3920023

    Sagamihara-shi, 252-0392
    Japan

    Site Not Available

  • Investigational Site Number :4400003

    Kaunas, 50161
    Lithuania

    Site Not Available

  • Investigational Site Number :4400002

    Klaipeda, 92288
    Lithuania

    Site Not Available

  • Investigational Site Number :4400004

    Siauliai, LT-76231
    Lithuania

    Site Not Available

  • Investigational Site Number :4400001

    Vilnius, 08661
    Lithuania

    Site Not Available

  • Investigational Site Number :4840002

    Ciudad de Mexico, 03100
    Mexico

    Site Not Available

  • Investigational Site Number :4840001

    Mexico, 06700
    Mexico

    Site Not Available

  • Investigational Site Number :4840002

    Mexico, 03100
    Mexico

    Site Not Available

  • Investigational Site Number :4840003

    Veracruz, 91910
    Mexico

    Site Not Available

  • Investigational Site Number :6160003

    Bydgoszcz, Kujawsko-pomorskie 85-796
    Poland

    Site Not Available

  • Investigational Site Number :6160005

    Warszawa, Mazowieckie 01-211
    Poland

    Site Not Available

  • Investigational Site Number :6160006

    Warszawa, Mazowieckie 01-684
    Poland

    Site Not Available

  • Investigational Site Number :6160009

    Glogow Mlp., Podkarpackie 36-060
    Poland

    Site Not Available

  • Investigational Site Number :6160002

    Katowice, Slaskie 40-571
    Poland

    Site Not Available

  • Investigational Site Number :6160004

    Katowice, Slaskie 40-686
    Poland

    Site Not Available

  • Investigational Site Number :6160008

    Plewiska, Wielkopolskie 62-064
    Poland

    Site Not Available

  • Investigational Site Number :6160001

    Lodz, 90-549
    Poland

    Site Not Available

  • Investigational Site Number :6420015

    Brasov, 500283
    Romania

    Site Not Available

  • Investigational Site Number :6420008

    Bucuresti, 022328
    Romania

    Site Not Available

  • Investigational Site Number :6420004

    Campulung, 115100
    Romania

    Site Not Available

  • Investigational Site Number :6420003

    Constanta, 900123
    Romania

    Site Not Available

  • Investigational Site Number :6420010

    Oradea, 410169
    Romania

    Site Not Available

  • Investigational Site Number :6420005

    Sibiu, 550052
    Romania

    Site Not Available

  • Investigational Site Number :6420001

    Targu Mures, 540136
    Romania

    Site Not Available

  • Investigational Site Number :6420002

    Timisoara, 300736
    Romania

    Site Not Available

  • Investigational Site Number :6430014

    Krasnoyarsk, 660029
    Russian Federation

    Site Not Available

  • Investigational Site Number :6430002

    Moscow, 125367
    Russian Federation

    Site Not Available

  • Investigational Site Number :6430008

    Moscow, 129128
    Russian Federation

    Site Not Available

  • Investigational Site Number :6430003

    Nizhny Novgorod, 603155
    Russian Federation

    Site Not Available

  • Investigational Site Number :6430011

    Nizhny Novgorod, 603137
    Russian Federation

    Site Not Available

  • Investigational Site Number :6430007

    Pyatigorsk, 357538
    Russian Federation

    Site Not Available

  • Investigational Site Number :6430012

    Rostov-on-Don, 344022
    Russian Federation

    Site Not Available

  • Investigational Site Number :6430005

    Samara, 443095
    Russian Federation

    Site Not Available

  • Investigational Site Number :6430009

    Smolensk, 214018
    Russian Federation

    Site Not Available

  • Investigational Site Number :6430001

    St-Petersburg, 194044
    Russian Federation

    Site Not Available

  • Investigational Site Number :6430006

    Tyumen, 625000
    Russian Federation

    Site Not Available

  • Investigational Site Number :6430004

    Ufa, 450005
    Russian Federation

    Site Not Available

  • Investigational Site Number :7240003

    Sevilla, Andalucia 41009
    Spain

    Site Not Available

  • Investigational Site Number :7240009

    Barcelona, Barcelona [Barcelona] 08035
    Spain

    Site Not Available

  • Investigational Site Number :7240001

    Pozuelo De Alarcón, Madrid 28223
    Spain

    Site Not Available

  • Investigational Site Number :7240008

    Donostia, Pais Vasco 20014
    Spain

    Site Not Available

  • Investigational Site Number :7240004

    Córdoba, 14004
    Spain

    Site Not Available

  • Investigational Site Number :7240006

    Murcia, 30120
    Spain

    Site Not Available

  • Investigational Site Number :7240005

    Málaga, 29010
    Spain

    Site Not Available

  • Investigational Site Number :7240007

    Valencia, 46026
    Spain

    Site Not Available

  • Investigational Site Number :7520001

    Göteborg, 413 45
    Sweden

    Site Not Available

  • Investigational Site Number :7520002

    Stockholm, 113 65
    Sweden

    Site Not Available

  • Investigational Site Number :1580007

    Hsinchu City, 30059
    Taiwan

    Site Not Available

  • Investigational Site Number :1580005

    Kaohsiung, 833
    Taiwan

    Site Not Available

  • Investigational Site Number :1580003

    Taichung, 402
    Taiwan

    Site Not Available

  • Investigational Site Number :1580002

    Taipei, 112
    Taiwan

    Site Not Available

  • Investigational Site Number :1580006

    Taoyuang, 333
    Taiwan

    Site Not Available

  • Investigational Site Number 7920002

    Cerrahpasa / Istanbul, 34098
    Turkey

    Site Not Available

  • Investigational Site Number :7920005

    Eskisehir,
    Turkey

    Site Not Available

  • Investigational Site Number :7920011

    Hatay,
    Turkey

    Site Not Available

  • Investigational Site Number :7920002

    Istanbul, 34098
    Turkey

    Site Not Available

  • Investigational Site Number :7920003

    Istanbul,
    Turkey

    Site Not Available

  • Investigational Site Number :7920007

    Istanbul, 34785
    Turkey

    Site Not Available

  • Investigational Site Number :7920009

    Istanbul, 34688
    Turkey

    Site Not Available

  • Investigational Site Number :7920008

    Izmir, 35100
    Turkey

    Site Not Available

  • Investigational Site Number :7920010

    Izmir,
    Turkey

    Site Not Available

  • Investigational Site Number :7920001

    Kocaeli, 41380
    Turkey

    Site Not Available

  • Investigational Site Number :7920006

    Mersin, 33070
    Turkey

    Site Not Available

  • Investigational Site Number :8040011

    Ivano-Frankivsk, 76493
    Ukraine

    Site Not Available

  • Investigational Site Number :8040013

    Kharkiv, 61103
    Ukraine

    Site Not Available

  • Investigational Site Number :8040016

    Kharkiv, 61068
    Ukraine

    Site Not Available

  • Investigational Site Number :8040008

    Kherson, 73000
    Ukraine

    Site Not Available

  • Investigational Site Number :8040014

    Kyiv, 03115
    Ukraine

    Site Not Available

  • Investigational Site Number :8040010

    Lutsk, 43005
    Ukraine

    Site Not Available

  • Investigational Site Number :8040001

    Lviv, 79010
    Ukraine

    Site Not Available

  • Investigational Site Number :8040009

    Odesa, 65025
    Ukraine

    Site Not Available

  • Investigational Site Number :8040012

    Zhytormyr, 10002
    Ukraine

    Site Not Available

  • University of Alabama MS Center-Site Number:8400013

    Birmingham, Alabama 35233
    United States

    Site Not Available

  • University of San Francisco, Sandler Neurosciences Center-Site Number:8400137

    San Francisco, California 94158
    United States

    Site Not Available

  • University of Colorado-Site Number:8400012

    Aurora, Colorado 80045
    United States

    Site Not Available

  • Georgetown University Medical Center-Site Number:8400119

    Washington, District of Columbia 20007
    United States

    Site Not Available

  • Beth Israel Deaconess Medical Center-Site Number:8400064

    Fort Myers, Florida 33919
    United States

    Site Not Available

  • Axiom Clinical Research of Florida-Site Number:8400001

    Tampa, Florida 33609-4052
    United States

    Site Not Available

  • University of South Florida-Site Number:8400006

    Tampa, Florida 33612
    United States

    Site Not Available

  • Meridian Clinical Research-Site Number:8400003

    Savannah, Georgia 31406
    United States

    Site Not Available

  • Consultants In Neurology-Site Number:8400011

    Northbrook, Illinois 60062
    United States

    Site Not Available

  • Tufts Medical Center-Site Number:8400072

    Boston, Massachusetts 02111
    United States

    Site Not Available

  • Michigan Institute For Neurological Disorders-Site Number:8400058

    Farmington Hills, Michigan 48334
    United States

    Site Not Available

  • The Memorial Hospital-Site Number:8400033

    Owosso, Michigan 48867
    United States

    Site Not Available

  • Sharlin Health & Neurology-Site Number:8400093

    Ozark, Missouri 65721
    United States

    Site Not Available

  • Missouri Baptist Medical Center-Site Number:8400019

    Saint Louis, Missouri 63131
    United States

    Site Not Available

  • Meridian Clinical Research, LLC-Site Number:8400005

    Raleigh, North Carolina 27607
    United States

    Site Not Available

  • Wake Forest University Baptist Medical Center-Site Number:8400116

    Winston-Salem, North Carolina 27157
    United States

    Site Not Available

  • Optimed Research, LTD-Site Number:8400147

    Columbus, Ohio 43235
    United States

    Site Not Available

  • The Ohio State University Wexner Medical Center-Site Number:8400150

    Columbus, Ohio 43221
    United States

    Site Not Available

  • Columbus Neuroscience-Site Number:8400010

    Westerville, Ohio 40382
    United States

    Site Not Available

  • Oklahoma Medical Research Foundation-Site Number:8400018

    Oklahoma City, Oklahoma 73104
    United States

    Site Not Available

  • Providence Multiple Sclerosis Center-Site Number:8400020

    Portland, Oregon 97225
    United States

    Site Not Available

  • University of Texas Southwestern Medical Center-Site Number:8400077

    Dallas, Texas 75390
    United States

    Site Not Available

  • Multiple Sclerosis Center, Swedish Neuroscience Institute-Site Number:8400121

    Seattle, Washington 98122
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.